Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer

Objective: to study hormone balance changes caused by various options of neoadjuvant chemotherapy (CT) in patients with breast cancer (BC). Materials and methods. Data on 200 patients aged 30 to 65 years with primary BC (Stages IIB-IIIA), who had been treated at the Rostov Cancer Research Institute...

Detaylı Bibliyografya
Asıl Yazarlar:	Yu. S. Sidorenko, O. I. Kit, A. E. Lisutin, O. M. Semiletkin
Materyal Türü:	Makale
Dil:	Russian
Baskı/Yayın Bilgisi:	ABV-press 2014-08-01
Seri Bilgileri:	Опухоли женской репродуктивной системы
Konular:	breast cancer neoadjuvant chemotherapy levels
Online Erişim:	https://ojrs.abvpress.ru/ojrs/article/view/264

Benzer Materyaller

Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options
Yazar:: Yu. S. Sidorenko, ve diğerleri
Baskı/Yayın Bilgisi: (2014-07-01)

Breast Cancer: Neoadjuvant Chemotherapy
Yazar:: Barbara F. Shea, ve diğerleri
Baskı/Yayın Bilgisi: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
Yazar:: Barbara F. Shea, ve diğerleri
Baskı/Yayın Bilgisi: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
Yazar:: Barbara F. Shea, ve diğerleri
Baskı/Yayın Bilgisi: (2015-05-01)

BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
Yazar:: A. R. Bosieva, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

A study of the assessment of pathological response to neoadjuvant chemotherapy in patients with breast cancer
Yazar:: Supriya Mallige, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Abbreviated breast MRI for evaluating breast cancer before initiation of neoadjuvant chemotherapy: A cross-sectional study
Yazar:: Arvin Arian, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period
Yazar:: N.P. Quirke, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Assessment of the Predictive Role of Ki-67 in Breast Cancer Patients’ Responses to Neoadjuvant Chemotherapy
Yazar:: Ghizlane Rais, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer
Yazar:: Jan Haussmann, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Differences in breast tumor response to neoadjuvant chemotherapy by race – Is obesity the key?
Yazar:: Ruvarashe Rumano, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
Yazar:: Haidi Abd El Zaher, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
Yazar:: Yushi Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in patients with locally advanced breast cancer
Yazar:: Aanchal Gupta, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
Yazar:: Suji Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival
Yazar:: Gilles Houvenaeghel, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

An ultrasound-based nomogram model in the assessment of pathological complete response of neoadjuvant chemotherapy in breast cancer
Yazar:: Jinhui Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer
Yazar:: Fa-you Lv, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients
Yazar:: Çiğdem Yıldırım, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Research progress of artificial intelligence in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer
Yazar:: Wei Wei, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Does Apoptotic Index Predict the Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma?
Yazar:: Gokce ASKAN, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients
Yazar:: Sabine Danzinger, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Multiparametric MRI-based radiomics combined with pathomics features for prediction of the efficacy of neoadjuvant chemotherapy in breast cancer
Yazar:: Nan Xu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
Yazar:: M. M. Tsyganov, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Accuracy of Breast Ultrasonography and Mammography in Comparison with Postoperative Histopathology in Breast Cancer Patients after Neoadjuvant Chemotherapy
Yazar:: Gilda Schmidt, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS
Yazar:: Y. V. Kukharev, ve diğerleri
Baskı/Yayın Bilgisi: (2016-02-01)

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer
Yazar:: Farhad Ghasemi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
Yazar:: Ling-Ming Tseng, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
Yazar:: I. V. Frai, ve diğerleri
Baskı/Yayın Bilgisi: (2014-08-01)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
Yazar:: Yuanyuan Shen, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
Yazar:: Kuojun Ren, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Study on the Relationship Between PTPRO Methylation in Plasma and Efficacy Neoadjuvant Chemotherapy in Patients with Early Breast Cancer
Yazar:: Liu XW, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Role of positron emission tomography in predicting early tumor response to neoadjuvant chemotherapy for breast cancer
Yazar:: N. G. Chanchikova, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy—A Prospective Study
Yazar:: Rexeena V. Bhargavan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status
Yazar:: Eunju Shin, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
Yazar:: Freshte Foroughi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Factors Affecting the Complete Response in Breast and Axillary Regions Following Neoadjuvant Chemotherapy for Breast Cancer
Yazar:: Halit Ozgul, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
Yazar:: P. V. Krivorotko, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Imaging‐proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer
Yazar:: Jingxian Duan, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Yazar:: Monika Drobniene, ve diğerleri
Baskı/Yayın Bilgisi: (2025-04-01)